Drum roll… In Vivo’s 2026 Rising Leaders were announced this week and included not one, not two, but five Optimum clients. A huge congratulations to Colleen Acosta of Freya Biosciences, Diana Čekatauskaitė of Lonza’s Synaffix, Reuben Dawkins of Link Biologics, Michelle Morrow of Nucleome Therapeutics, and Javier Nunez-Vicandi of Sofinnova Partners. This list recognises not […]
Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief Scientific Officer Janine Schuurman, PhD, Hans Clevers, MD, PhD, and David Sansom, PhD, join the Scientific Advisory Board Appointments strengthen Laigo’s leadership team following its €17m seed financing as the Company advances its SureTACs™ programs towards clinical development UTRECHT, […]
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity. UTRECHT, the Netherlands – 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering […]
